Efficacy and safety of anthracyclines in combination with taxanes for neo-adjuvant chemotherapy in patients with breast cancer
LIU Wei
LI Jianbin
WANG Tao
BIAN Li
ZHANG Shaohua
ZHANG Huiqiang
ZHOU Jinmei
SONG Santai
JIANG Zefei
Abstract：Objective To assess the efficacy and safety of anthracyclines in combination with taxanes for neo?adjuvant chem?otherapy in patients with breast cancer. Methods The data of 192 breast cancer patients treated by taxanes and anthracyclines neoad?juvant regimens was reviewed. The efficacy and safety of taxanes and anthracyclines neoadjuvant regimens, as well as factors influencing pathological complete remission were analyzed. Results The efficacy of 192 patients could be evaluated. The effective rate was 84?9%(163/192),and the overall pathologic complete remission rate was 20?3%(39/192). The complete remission rates were 8?5%(10/118) in patients of HR(+)/HER?2(-) subtype, 42?8%( 6/8) in patients of HR(-)/HER?2(+) subtype, 25?0%( 5/20) in patents of HR(+)/HER?2(+) subtype, and 45?0%( 18/40) in patients of HR?/HER?2?subtype. The logistic regression revealed that ER status affected the complete remission rate after neoadjuvant chemotherapy of the breast cancer. The main dose limiting toxicities was grade 3/4 neutropenia ( 94?7%) . Other non?hematologic toxicities included grade 2/3 vomitting ( 6?2%) , bone pain ( 14?1%) , febrile neutro?penia ( 16?7%) , mucocitis ( 2?1%) and cardiotoxicity ( 5?7%) and etc. Conclusion Taxanes and anthracyclines chemotherapy regi?mens for the treament of patients with confirmed breast cancer show satisfied efficacy and safety, which can be regarded as an optimal neoadjuvant regimen for breast cancer.
Keywords：Breast cancerAnthracyclinesTaxanesNeoadjuvant chemotherapyPathologic complete response
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 228-232 )